Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer.

Respiratory research - 23 May 2026

Lin Jie, Xia Guojie, Wu Yijuan, Chen Lingfeng, Zhang Yaru, Ma Ya, Yin Jiani C, Zhang Zhenyu, Pan Xiaojie

Abstract excerpt

BACKGROUND: MET exon 14 skipping mutation (METΔex14) is a key driver event in non-small cell lung cancer (NSCLC) and can emerge as an acquired drug resistance mechanism to MET, EGFR or ALK inhibitors. The clinical and genomic features of METΔex14 in NSCLC require further characterization. METHODS: Our study included a total of 585 patients with METΔex14 + NSCLC, comprising 556 baseline samples, 53 samples from...

Read the complete abstract on PubMed

Topics

Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Proto-Oncogene Proteins c-met
Mutation
Exons

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Female

Male

Middle Aged

Aged

Drug Resistance, Neoplasm

Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 42174600
DOI: 10.1186/s12931-026-03626-1
PMCID: PMC13536711

Genes

MET
EGFR
ALK
CDK4
FGFR3
TACC3
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer.PMID 42174600Read ↗

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesSemantic proximity Read ↗

MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation.Semantic proximity Read ↗

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experienceSemantic proximity Read ↗

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.Semantic proximity Read ↗

<i>MET</i> Exon 14 Skipping in Non-Small Cell Lung CancerSemantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.Semantic proximity Read ↗

MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.Semantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

MET alterations in NSCLC-Current Perspectives and Future Challenges.Semantic proximity Read ↗

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.